Dianthus Therapeutics, Inc./$DNTH
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Dianthus Therapeutics, Inc.
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.
Ticker
$DNTH
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
78
ISIN
US2528281080
Website
DNTH Metrics
BasicAdvanced
$654M
-
-$2.81
-
-
Price and volume
Market cap
$654M
52-week high
$24.81
52-week low
$13.37
Average daily volume
339K
Financial strength
Current ratio
15.985
Quick ratio
15.586
Long term debt to equity
0.356
Total debt to equity
0.425
Profitability
EBITDA (TTM)
-117.096
Gross margin (TTM)
100.00%
Net profit margin (TTM)
-1,544.02%
Operating margin (TTM)
-1,796.40%
Revenue per employee (TTM)
$80,000
Management effectiveness
Return on assets (TTM)
-20.04%
Return on equity (TTM)
-28.73%
Valuation
Price to revenue (TTM)
111.81
Price to book
1.99
Price to tangible book (TTM)
1.99
Price to free cash flow (TTM)
-8.019
Free cash flow yield (TTM)
-12.47%
Free cash flow per share (TTM)
-253.77%
Growth
Revenue change (TTM)
102.36%
Earnings per share change (TTM)
-36.47%
Bulls say / Bears say
TD Cowen initiated coverage of Dianthus Therapeutics with a 'Buy' recommendation, indicating strong confidence in the company's future prospects. (nasdaq.com)
Dianthus Therapeutics successfully completed a $230 million private placement in January 2024, significantly bolstering its financial position to support ongoing and future projects. (tradingview.com)
The company has multiple clinical trials underway, including the Phase 2 MaGic trial for generalized Myasthenia Gravis, with top-line results expected in the second half of 2025, potentially leading to new treatment approvals. (stocktitan.net)
Dianthus Therapeutics reported a Q4 loss of $0.81 per share, missing revenue estimates and indicating ongoing financial challenges. (nasdaq.com)
The company has a history of missing earnings estimates, having surpassed consensus EPS estimates only once in the last four quarters, raising concerns about financial performance consistency. (nasdaq.com)
Despite significant investments, the success of ongoing clinical trials remains uncertain, and any negative outcomes could adversely affect the company's stock value. (stocktitan.net)
Data summarised monthly by Lightyear AI. Last updated on 8 Jul 2025.
DNTH News
AllArticlesVideos
Dianthus Therapeutics to Webcast Presentation at the Jefferies Global Healthcare Conference
GlobeNewsWire·2 months ago
Dianthus Therapeutics Appoints Simon Read, Ph.D., to Board of Directors
GlobeNewsWire·2 months ago
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q1 Financial Results
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Dianthus Therapeutics, Inc. stock?
Dianthus Therapeutics, Inc. (DNTH) has a market cap of $654M as of July 18, 2025.
What is the P/E ratio for Dianthus Therapeutics, Inc. stock?
The price to earnings (P/E) ratio for Dianthus Therapeutics, Inc. (DNTH) stock is 0 as of July 18, 2025.
Does Dianthus Therapeutics, Inc. stock pay dividends?
No, Dianthus Therapeutics, Inc. (DNTH) stock does not pay dividends to its shareholders as of July 18, 2025.
When is the next Dianthus Therapeutics, Inc. dividend payment date?
Dianthus Therapeutics, Inc. (DNTH) stock does not pay dividends to its shareholders.
What is the beta indicator for Dianthus Therapeutics, Inc.?
Dianthus Therapeutics, Inc. (DNTH) does not currently have a Beta indicator.